Breakthrough Eli Lilly Drug Lowers Heart Attack Risk by Targeting Mysterious Lp(a) Particles

Many people in the U.S.—about 64 million or one in five—have high levels of a cholesterol-like particle in their blood called Lp(a). This particle can significantly boost the chances of heart attacks and strokes, yet most of us know little about it. Surprisingly, most doctors don’t routinely test for it. That’s mainly because until recently, there wasn’t much to do about it with diet, exercise, or medications.

However, this could change soon. At a recent meeting of the American College of Cardiology, researchers announced exciting news about an experimental drug from Eli Lilly called lepodisiran. This innovative treatment could reduce Lp(a) levels by up to 94% with just one injection, and the benefits could last for six months without notable side effects.

Dr. David Maron, a preventive cardiologist at Stanford University, described the results as "thrilling." He noted that the ability to drastically lower Lp(a) levels could be a game-changer in heart disease prevention. But it’s essential to remember that this news is still preliminary. We need more extensive clinical trials to determine whether lowering Lp(a) also cuts down the risk of heart problems.

The significance of this development is heightened when we look at historical advancements in cardiovascular treatments. For decades, high cholesterol was the main focus in preventing heart disease, with various treatments available to manage it. The rise of Lp(a) awareness could lead to a new chapter in heart health, echoing how public health shifts when new knowledge emerges.

Other companies are also joining the race to find treatments that target Lp(a). This includes several innovative therapies currently under investigation, making it an exciting time in the field of cardiology.

While we wait for more concrete evidence, it’s clear that awareness and education about Lp(a) are crucial. Conversations about heart health are changing, and soon they might include discussions about reducing Lp(a) levels as a preventive strategy.

For those interested in exploring this topic further, the findings were published in the New England Journal of Medicine. Staying informed can help you take proactive steps towards better heart health.

Source link

Heart,Lipoproteins,Drugs (Pharmaceuticals),Clinical Trials,Stroke,Research,Eli Lilly and Company,New England Journal of Medicine